Benitec Biopharma (BNTC) to Release Quarterly Earnings on Wednesday

Benitec Biopharma (NASDAQ:BNTC) will likely be issuing its Q3 2026 results before the market opens on Wednesday, May 13th. Analysts expect Benitec Biopharma to post earnings of ($0.27) per share and revenue of $4.55 million for the quarter. Investors may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03). On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Benitec Biopharma Stock Up 0.2%

Shares of Benitec Biopharma stock opened at $12.20 on Wednesday. The stock’s fifty day moving average is $11.67 and its two-hundred day moving average is $12.50. Benitec Biopharma has a 52 week low of $9.85 and a 52 week high of $17.15. The company has a market capitalization of $419.07 million, a PE ratio of -10.70 and a beta of 0.28.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Benitec Biopharma in a research note on Monday, March 9th. Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Finally, TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, March 9th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Benitec Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Institutional Trading of Benitec Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC grew its holdings in Benitec Biopharma by 16.9% during the 4th quarter. Suvretta Capital Management LLC now owns 11,548,351 shares of the biotechnology company’s stock worth $155,556,000 after acquiring an additional 1,671,845 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Benitec Biopharma by 7.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,120,672 shares of the biotechnology company’s stock valued at $28,565,000 after purchasing an additional 148,148 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Benitec Biopharma in the 4th quarter worth approximately $24,920,000. Nantahala Capital Management LLC lifted its position in shares of Benitec Biopharma by 23.9% in the 4th quarter. Nantahala Capital Management LLC now owns 1,038,371 shares of the biotechnology company’s stock worth $13,987,000 after purchasing an additional 200,276 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Benitec Biopharma by 2.4% during the third quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company’s stock valued at $13,919,000 after purchasing an additional 22,948 shares in the last quarter. 52.19% of the stock is owned by hedge funds and other institutional investors.

About Benitec Biopharma

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.